The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Kolkova, Zuzana ^a   Casslén, Vera ^a   Henic, Emir ^a   Ahmadi, Sara ^a   Ehinger, Anna ^a   Jirström, Karin ^a   Casslén, Bertil ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

borderline tumors; ER; immunohistochemistry; ovarian cancer cell lines; TMA

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; MESSENGER RNA;

ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 84858201263     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-9     Document Type: Article

References (33)

1. Estrogen stimulation of ovarian surface epithelial cell proliferation. Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV, In Vitro Cell Dev Biol Anim 2000 36 10 657 666 10.1290/1071-2690(2000)036<0657: ESOOSE>2.0.CO;2 11229598 (Pubitemid 32164666)
2. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC, Endocrinology 2001 142 6 2351 2360 10.1210/en.142.6.2351 11356682 (Pubitemid 32473090)
3. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Lindgren P, Backstrom T, Mahlck CG, Ridderheim M, Cajander S, Int J Oncol 2001 19 1 31 38 11408919
4. Involvement of estrogen receptor beta in ovarian carcinogenesis. Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P, Lazennec G, Cancer Res 2004 64 16 5861 5869 10.1158/0008-5472.CAN-04-0552 15313930 (Pubitemid 39095587)
5. The different roles of ER subtypes in cancer biology and therapy. Thomas C, Gustafsson JA, Nat Rev Cancer 2011 11 8 597 608 10.1038/nrc3093 21779010
6. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Thomas P, Pang Y, Filardo EJ, Dong J, Endocrinology 2005 146 2 624 632 15539556 (Pubitemid 40129818)
7. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER, Science 2005 307 5715 1625 1630 10.1126/science.1106943 15705806 (Pubitemid 40354745)
8. G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments. Sanden C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J, Martensson UE, Olde B, Leeb-Lundberg LM, Molecular pharmacology 2011 79 3 400 410 10.1124/mol.110.069500 21149639
9. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr, Mol Endocrinol 2000 14 10 1649 1660 Baltimore, Md 10.1210/me.14.10.1649 11043579
10. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, et al. Cancer Res 2007 67 4 1859 1866 10.1158/0008-5472.CAN-06-2909 17308128 (Pubitemid 46383413)
11. GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERalpha) phosphorylation signals. Gao F, Ma X, Ostmann AB, Das SK, Endocrinology 2011 152 4 1434 1447 10.1210/en.2010-1368 21303939
12. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, Jirstrom K, Journal of ovarian research 2010 3 14 10.1186/1757-2215-3-14 20565760
13. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K, Translational oncology 2011 4 4 212 221 21804916
14. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al. J Transl Med 2010 8 78 10.1186/1479-5876-8-78 20727170
15. Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. Brennan DJ, Brandstedt J, Rexhepaj E, Foley M, Ponten F, Uhlen M, Gallagher WM, O'Connor DP, O'Herlihy C, Jirstrom K, BMC Cancer 2010 10 125 10.1186/1471-2407-10-125 20359358
16. Discovery of Dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer. Nodin B, Fridberg M, Uhlen M, Jirstrom K, Journal of ovarian research 2012 5 1 6 10.1186/1757-2215-5-6 22284433
17. Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Noskova V, Ahmadi S, Asander E, Casslen B, Gynecol Oncol 2009 115 1 121 126 10.1016/j.ygyno.2009. 06.026 19631971
18. G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. Kolkova Z, Noskova V, Ehinger A, Hansson S, Casslen B, Molecular human reproduction 2010 16 10 743 751 10.1093/molehr/gaq043 20508064
19. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, Borgquist S, Uhlen M, Landberg G, Pahlman S, et al. Mod Pathol 2009 22 12 1564 1574 10.1038/modpathol.2009.124 19734850
20. GPR30 predicts poor survival for ovarian cancer. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER, Gynecologic oncology 2009 114 3 465 71 10.1016/j.ygyno.2009.05.015 19501895
21. Distribution of GPR30, a Seven Membrane-Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, Delellis RA, Steinhoff MM, Sabo E, Clin Cancer Res 2006 12 21 6359 6366 10.1158/1078-0432.CCR-06-0860 17085646 (Pubitemid 44799705)
22. GPR30: a novel indicator of poor survival for endometrial carcinoma. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER, Am J Obstet Gynecol 2007 196 4 386 e381 386 e389 discussion 386 e389-311
23. The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Kuo WH, Chang LY, Liu DL, Hwa HL, Lin JJ, Lee PH, Chen CN, Lien HC, Yuan RH, Shun CT, et al. Taiwan J Obstet Gynecol 2007 46 2 135 145 10.1016/S1028-4559(07)60007-2 17638621 (Pubitemid 47236783)
24. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM, Cell Death Differ 2010 17 9 1511 1523 10.1038/cdd.2010.20 20203690
25. The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle. Holm A, Baldetorp B, Olde B, Leeb-Lundberg LM, Nilsson BO, J Vasc Res 2011 48 4 327 335 10.1159/000322578 21273787
26. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA, Cancer Res 2009 69 13 5415 5423 10.1158/0008-5472.CAN-08-1622 19549922
27. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY, Obstet Gynecol 2008 111 1 144 151 10.1097/01.AOG.0000296715.07705.e9 18165403
28. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD, Kalinski T, Breast cancer research and treatment 2011 128 2 457 466 10.1007/s10549-011-1584-1 21607586
29. The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Teng J, Wang ZY, Prossnitz ER, Bjorling DE, Endocrinology 2008 149 8 4024 4034 10.1210/en.2007-1669 18467434
30. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Park SH, Cheung LW, Wong AS, Leung PC, Mol Endocrinol 2008 22 9 2085 2098 Baltimore, Md 10.1210/me.2007-0512 18550773
31. Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. Henic E, Noskova V, Hoyer-Hansen G, Hansson S, Casslen B, Int J Gynecol Cancer 2009 19 2 214 222 10.1111/IGC.0b013e31819bcb75 19395996
32. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC Jr, Am J Obstet Gynecol 1991 164 2 669 674 1992720
33. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A, Mancuso S, Br J Cancer 1995 72 2 361 366 10.1038/bjc.1995.339 7640219